



Biodesix Announces Pricing of Initial Public Offering

October 28, 2020

BOULDER, Colo.--(BUSINESS WIRE)--Oct. 28, 2020-- Biodesix, Inc. (Nasdaq: BDSX) ("Biodesix") today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of \$18.00 per share. The shares are expected to begin trading on The Nasdaq Global Market on October 28, 2020, under the symbol "BDSX." The offering is expected to close on October 30, 2020, subject to the satisfaction of customary closing conditions. In addition, Biodesix has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Morgan Stanley and William Blair are acting as lead book-running managers for the offering. Canaccord Genuity is acting as lead manager and BTIG is acting as co-manager for the proposed offering.

The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at prospectus@morganstanley.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.

A registration statement relating to the shares being sold in this offering has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201028005419/en/): <https://www.businesswire.com/news/home/20201028005419/en/>

Jeremy Feffer
jeremy@lifesciadvisors.com

Source: Biodesix, Inc.